

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liao et al.

Art Unit: 1614

Application No. 09/634,369

Filed: August 9, 2000

For: ANTI-INFLAMMATORY ACTIONS OF
CYTOCHROME P450 EPOXYGENASE-
DERIVED EICOSANOIDS

Examiner: Cybille Delacroix-Muirheid

Date: April 25, 2003

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with Federal Express via Airbill No. 8359 2173 3114 on April 25, 2003 in an envelope addressed to: Crystal Mall 1, 7th Floor Receptionist, 11 S. Clark St., Arlington, VA 22202.

Agent for Applicants

RECEIVED
TECH CENTER 1600/2900
APR 28 9:55 AM


STATEMENT IN COMPLIANCE WITH 37 C.F.R. § 1.821(f)

COMMISSIONER FOR PATENTS
CRYSTAL MALL 1
7TH FLOOR RECEPTIONIST
1911 S. CLARK ST.
ARLINGTON, VA 22202

In compliance with 37 C.F.R. § 1.821(f), the undersigned declares that the nucleotide and/or amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of said "Sequence Listing." No new matter has been added.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. Other: _____

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF submission help, call (703) 308-4212
- For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.

COPY